Probability of VZV disease for 2 years after transplantation in allogeneic HCT recipients and autologous HCT recipients. (A) Among allogeneic HCT recipients, the probability of VZV reactivation disease was significantly lower in cohort 2 (8.8%; P < .001) and in cohort 3 (4.5%; P < .001) compared with cohort 1 (24.9%), and in cohort 3 compared with cohort 2 (P = .01). (B) Among autologous HCT recipients, the probability of VZV reactivation disease was significantly lower in cohorts 2 and 3 (8.2%; P < .001) compared with cohort 1 (21.7%).